Eliminating the third BACE2 copy in T21 resulted in AmyloGlo+ deposits with neuritic plaques and neuron loss, while the trisomic BACE2 level protected against early amyloid plaque pathology, suggesting BACE2 as a therapeutic target to delay AD onset. The gene discussed is BACE2; the disease is amyloidosis.